Doximity: Buy Rating Backed by Solid Q4 Results, Cyclical Pharma Headwinds, and Long-Term AI Growth Strategy

William Blair analyst Ryan Daniels has maintained their bullish stance on DOCS stock, giving a Buy rating today.

Ryan Daniels has given his Buy rating due to a combination of factors, starting with Doximity’s solid fiscal fourth-quarter performance, which modestly exceeded expectations on both revenue and adjusted EBITDA despite cautious pharma marketing budgets. While fiscal 2027 revenue guidance is slightly below consensus as life sciences clients trim and shorten commitments, he views this as a cyclical headwind rather than a structural impairment to the business.

Daniels also highlights management’s strategic push into artificial intelligence as a key long‑term growth catalyst, with 2027 positioned as an investment year that is already driving higher physician engagement and the early commercialization of AI tools, including paid search, opening a sizable new market opportunity. In addition, the appointment of an experienced new CFO, who already knows the company well, should support effective capital allocation and operational execution, reinforcing confidence in Doximity’s ability to navigate near‑term volatility and create shareholder value over time.

According to TipRanks, Daniels is an analyst with an average return of -1.1% and a 40.44% success rate. Daniels covers the Healthcare sector, focusing on stocks such as HealthStream, TransMedics Group, and OptimizeRx.

In another report released today, Needham also reiterated a Buy rating on the stock with a $27.00 price target.